Dexcom is pleased to announce that the U.S. Centers for Medicare & Medicaid Services (CMS) has published an article clarifying criteria for coverage and coding of the Dexcom G5 Mobile system, the only therapeutic CGM under this CMS classification. People covered by Medicare who have either Type 1 or Type 2 diabetes and intensively manage their insulin will now be able to obtain reimbursement.
EDINBURGH, Scotland, January 10, 2017 - DexCom, Inc. (NASDAQ:DXCM), the leader in Continuous Glucose Monitoring (CGM) for patients with diabetes, announced today that its G5 Mobile CGM System is now compatible on Android smart devices throughout Europe and South Africa. This new platform will be launching into select European countries today and continue throughout the fourth quarter of 2017.
Today, the Dexcom One Step Ahead Foundation: A Dexcom Employees Foundation, awarded its first grants to five public charity organizations dedicated to improving the lives of people with diabetes. Grants were awarded to the following organizations: the American Youth Understanding Diabetes Abroad (AYUDA), College Diabetes Network, DiabetesSisters, Riding On Insulin, and Type-1-Today/Children with Diabetes (CWD). The grants were awarded by the employee-funded philanthropy, launched three months ago by Dexcom employees passionate about doing more for the diabetes community.
Landmark approval marks a new standard of care for managing diabetes and dosing insulin in Canada
BURNABY, British Columbia, Nov. 14, 2016 - Dexcom, the leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that Health Canada has approved its Dexcom G5 Mobile CGM system for "non-adjunctive" use by people with diabetes aged 2 years and older. DexCom, Inc.